^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    COX2 inhibitor

    Related drugs:
    2d
    Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2. (PubMed, Eur J Med Res)
    Combination treatment with shikonin and COX-2 inhibitor may be a suitable therapeutic strategy for EGFR-T790M-mutant NSCLC treatment.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ANXA5 (Annexin A5) • GSDME (Gasdermin E)
    |
    EGFR mutation • EGFR T790M • PTGS2 expression
    |
    celecoxib oral
    4d
    Photodynamic Therapy-Induced Immune Modulation: Part III (clinicaltrials.gov)
    P1, N=12, Terminated, Wright State University | Completed --> Terminated; Per PI due to data analysis results.
    Trial termination
    |
    celecoxib oral
    12d
    A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα. (PubMed, Front Pharmacol)
    Comparison of the inhibition of COX-2 and its reversibility by AA520, indomethacin (a time-dependent inhibitor), acetylsalicylic acid (ASA) (an irreversible inhibitor), and ibuprofen (a reversible inhibitor) showed that the compound is acting by forming a tightly bound COX-2 interaction. This inhibitor retains PPARα antagonism at the same concentration range. It has the potential to be effective in treating certain types of cancer, such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), where COX-2 and PPARα are overexpressed.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    PTGS2 expression
    |
    aspirin
    13d
    Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, South Rampart Pharma, LLC | Trial completion date: Feb 2024 --> Mar 2026 | Trial primary completion date: Oct 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    13d
    Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Our study shows the important role of COX-2 in CAFs by promoting immune suppression. Our results suggested that high expression of COX-2 in CAFs may serve as a new therapeutic, targeting CAFs in enhancing immune responses in breast cancer treatment.
    Journal
    |
    IFNG (Interferon, gamma) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3) • IL4 (Interleukin 4)
    |
    IFNG expression • PTGS2 expression • FOXP3 expression
    |
    celecoxib oral
    14d
    Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Air Force Military Medical University, China
    New trial
    |
    celecoxib oral
    14d
    Reduced Opioid Prescription After Laparoscopic Hysterectomy (clinicaltrials.gov)
    P=N/A, N=120, Active, not recruiting, Johns Hopkins University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    19d
    Dexketoprofen Dosage According to Chronotherapy (clinicaltrials.gov)
    P=N/A, N=10, Completed, Universidad Complutense de Madrid | Not yet recruiting --> Completed | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Jul 2023 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    19d
    Discovery of a molecular glue for EGFR degradation. (PubMed, Oncogene)
    Notably, CDDO-Me attenuates TNBC progression by accelerating EGFR degradation in cell-derived xenografts and patient-derived organoid models, highlighting its clinical application potential. Consequently, induction of EGFR degradation through MG degraders represents a viable therapeutic strategy for TNBC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    19d
    Chrysanthemum indicum L. ameliorates muscle atrophy by improving glucose tolerance in CT26-induced cancer cachexia. (PubMed, Front Pharmacol)
    After 1 week, the mice were orally administered vehicle, CI (100 mg/kg), or Celecoxib (50 mg/kg) for 3 weeks...Furthermore, we found that linarin, a constituent of CI, was responsible for the improvement of muscle atrophy. Our findings indicate that CI can ameliorate muscle atrophy by improving glucose uptake, suggesting that CI could be a therapeutic agent for cancer cachexia.
    Journal
    |
    SLC2A4 (Solute Carrier Family 2 Member 4)
    |
    celecoxib oral
    20d
    99Tc-MDP Treatment for Knee Osteoarthritis (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    celecoxib oral
    20d
    Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=82, Terminated, Emory University | Phase classification: P1 --> P2 | Trial completion date: Oct 2024 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Feb 2024; This study was terminated after interim analyses showed no benefits.
    Phase classification • Trial completion date • Trial termination • Trial primary completion date • Surgery
    25d
    Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway. (PubMed, Inflammation)
    At the molecular level, ETO downregulated the protein expression of toll-like receptor 4 (TLR4), nuclear factor kappa-B (NF-κB), and p38 mitogen-activated protein kinase (p38 MAPK) in inflamed rat lungs. In conclusion, our findings indicate that oral administration of ETO ameliorates MTX-induced lung injury by inhibiting oxidative stress and suppressing the TLR4/NF-κB and TLR4/p38-MAPK inflammatory signaling pathways.
    Preclinical • Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
    |
    methotrexate
    25d
    Immunohistochemical Investigation of Cyclooxygenase-2 Expression in Rabbit Uterine Adenocarcinoma and the Potential Use of COX-2 Inhibitors in Cancer Therapy. (PubMed, Animals (Basel))
    Of the six cases of endometrial adenocarcinoma with follow-up available, four received a post-surgical treatment with meloxicam and two were treated by surgery alone...Our findings suggest the possible use of COX-2 inhibitors in treating uterine adenocarcinoma in rabbits. Further study will be needed to confirm this hypothesis.
    Preclinical • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    PTGS2 expression
    26d
    Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain (clinicaltrials.gov)
    P3, N=190, Completed, Laboratorios Silanes S.A. de C.V. | Recruiting --> Completed | Trial completion date: Jan 2025 --> Oct 2024
    Trial completion • Trial completion date
    28d
    Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients (clinicaltrials.gov)
    P4, N=68, Not yet recruiting, Universidad Austral de Chile
    New P4 trial
    1m
    Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery (clinicaltrials.gov)
    P3, N=148, Completed, TriHealth Inc. | Active, not recruiting --> Completed
    Trial completion • Surgery
    1m
    Stony Brook Medicine Anti-Inflammatory Trial (clinicaltrials.gov)
    P4, N=42, Not yet recruiting, Stony Brook University
    New P4 trial
    |
    celecoxib oral • minocycline
    1m
    pH-Activatable Molecular Probe for COX-2 Imaging in Human Oral Squamous Carcinoma Cells and Patient-Derived Tissues. (PubMed, ACS Appl Bio Mater)
    We have developed an SMPD, cyclooxygenase-2 (COX-2) targeting pH-activable fluorophore named CNP, combining a potent COX-2 inhibitor, celecoxib, linked to a naphthalimide fluorophore with an acidic microenvironment-responsive piperazine moiety for specific optical imaging of OSCC in cells and patient tissues...Further, CNP is demonstrated in imaging OSCC cells in patient-derived biopsies. Thus, multifunctional CNP shows potential in exploring more reagents for fluorescence-based detection of OSCC cells in patient tissues with translational applications.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    PTGS2 expression
    |
    celecoxib oral
    1m
    Garlic peel extract as an antioxidant inhibits triple-negative breast tumor growth and angiogenesis by inhibiting cyclooxygenase-2 expression. (PubMed, Food Sci Nutr)
    Immunohistochemistry was employed to assess the expression levels of COX-2, CD31, VEGFA, MMP2, and MMP9 in tumor tissues in order to investigate the antioxidant properties of garlic peel extract, specifically its ability to suppress COX-2 expression. The findings of this study offer a foundation for the advancement of garlic peel-based functional products and contribute to the identification of potential anti-cancer agents and therapeutic targets.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MMP9 (Matrix metallopeptidase 9) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    CD31 expression • PTGS2 expression
    1m
    INFLAMED: Treating Immuno-metabolic Depression With Anti-inflammatory Drugs (clinicaltrials.gov)
    P3, N=140, Recruiting, Amsterdam UMC, location VUmc | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    celecoxib oral
    1m
    The Effect of Celecoxib on Neuroinflammation in MDD (clinicaltrials.gov)
    P4, N=42, Recruiting, Stony Brook University | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    celecoxib oral
    1m
    1,5- diaryl pyrazole-loaded chitosan nanoparticles as COX-2 inhibitors, mitigate neoplastic growth by regulating NF-κB pathway in-vivo zebrafish model. (PubMed, Int J Biol Macromol)
    The gene expression analysis confirmed the decrease in the expression of anti-inflammatory genes, such as cox-2 and nf-κb, and apoptosis inhibitor genes, such as bcl-2 and mdm2. By regulating the anti-inflammatory and apoptosis inhibitor genes, FA-CS-DP nanoparticle prevents neoplastic growth in the zebrafish model.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1m
    Perioperative propranolol and celecoxib (ProCel) in stage III melanoma (ACTRN12624001353583)
    P2, N=40, Not yet recruiting, Sydney Local Health District
    New P2 trial • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • B2M (Beta-2-microglobulin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ICOS (Inducible T Cell Costimulator) • SOX10 (SRY-Box 10) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • VIM (Vimentin) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • HLA-E (Major Histocompatibility Complex, Class I, E) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FOXP3 (Forkhead Box P3) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • ITGAX (Integrin Subunit Alpha X) • MITF (Melanocyte Inducing Transcription Factor) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CD1C (CD1c Molecule) • TCF7 (Transcription Factor 7) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex) • S100B (S100 Calcium Binding Protein B)
    |
    celecoxib oral
    1m
    Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Gynecological Surgery (clinicaltrials.gov)
    P4, N=178, Completed, Rajavithi Hospital | Recruiting --> Completed
    Trial completion
    |
    Dynastat (parecoxib)
    1m
    Effect of Parecoxib sodium combined with esketamine and incision infiltration on postoperative analgesia and postoperative delirium (ChiCTR2400090230)
    P4, N=44, Completed, Taian City Central Hospital; Taian City Central Hospital
    New P4 trial
    |
    IL6 (Interleukin 6)
    |
    Dynastat (parecoxib) • Sufenta (sufentanil)
    2ms
    Celecoxib for ENT Pain Management (clinicaltrials.gov)
    P2, N=84, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    celecoxib oral
    2ms
    Cytobiological Alterations Induced by Celecoxib as an Anticancer Agent for Breast and Metastatic Breast Cancer. (PubMed, Adv Pharm Bull)
    These mechanisms collectively hinder tumor growth, immune evasion, and metastatic spread. By synthesizing recent findings and analyzing the impact of celecoxib on these pathways, this paper seeks to delineate the integrated approaches necessary for managing metastatic breast cancer effectively.
    Review • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR positive + HER-2 positive
    |
    celecoxib oral
    2ms
    CARES for Kids: Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial (clinicaltrials.gov)
    P4, N=900, Not yet recruiting, University of Michigan
    New P4 trial • Surgery
    |
    celecoxib oral
    2ms
    Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS (clinicaltrials.gov)
    P4, N=44, Active, not recruiting, Lawson Health Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Jul 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    aspirin • celecoxib oral
    2ms
    The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome (clinicaltrials.gov)
    P4, N=78, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    hydroxychloroquine
    2ms
    The methionine cycle and its cancer implications. (PubMed, Oncogene)
    Accordingly, Celecoxib, a specific NR4A2 inhibitor, is a potentially powerful inhibitor of tumor growth at least in this specific model. Additionally, formaldehyde, from endogenous or exogenous sources, can directly regulate both SAM steady-state-levels and the one-carbon metabolism, with relevant implication in cancer progression. These recent scientific advancements have provided a deeper understanding of the molecular mechanisms involved in cancer development, and its potential therapeutic regulation.
    Review • Journal
    |
    TP53 (Tumor protein P53) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
    |
    celecoxib oral
    2ms
    Asiatic acid impedes NSCLC progression by inhibiting COX-2 and modulating PI3K signaling. (PubMed, FEBS Lett)
    It also shows negative osmotic fragility on healthy human erythrocytes. It is concluded that AA may be a viable therapeutic drug for non-small cell lung cancer treatment, which opens new opportunities for synthesizing analogues.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    2ms
    Mitigation of radiation-induced jejunum injuries in rats through modulation of the p53-miR34a axis using etoricoxib-loaded nanostructured lipid carriers. (PubMed, Sci Rep)
    A histopathological examination confirmed that Et-NLC treatments had attenuated radiation damage, which had improved vascularization and reduced inflammation. The findings show that Et-NLC is more effective than Et-alone at reducing damage to the jejunum caused by radiation by controlling inflammation, oxidative stress, and apoptotic activity.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • MIR34A (MicroRNA 34a-5p) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    2ms
    Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors. (PubMed, ESMO Open)
    Leptin is a reliable predictive marker for multitargeted anti-cachectic treatment outcomes. Thus, it can be an ideal candidate for monitoring and predicting the effects of anti-cachectic treatment and a surrogate marker of the immune-metabolic actions of the selected drugs.
    Journal
    |
    LEP (Leptin)
    |
    megestrol • celecoxib oral
    3ms
    PRECISE: Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    Dynastat (parecoxib)
    3ms
    Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. (PubMed, Mol Cancer)
    Consequently, this process results in the pathological activation of the PI3K/Akt pathway. In summary, our study provides a new treatment strategy and novel biological target for patients with drug-resistant pancreatic cancer.
    Journal
    |
    CTSL (Cathepsin L)
    |
    gemcitabine • albumin-bound paclitaxel
    3ms
    Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies. (PubMed, Mol Divers)
    Drug repurposing on 626 FDA-approved drugs for digestive system-related cancers revealed Norgestimate and Nimesulide as likely top candidates for gastric cancer, validated by molecular docking and dynamics simulations...These findings support the therapeutic potential of targeting beta-actin protein in gastric cancer treatment, suggesting a future for further experimental validation and clinical translation. In conclusion, this study highlights the potential of repurposable drugs and virtual screening which can be used in combination with existing anti-gastric cancer drugs for gastric cancer therapy, emphasizing the role of computational methodologies in drug discovery.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    3ms
    Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study. (PubMed, Inflammopharmacology)
    Celecoxib could be a promising adjuvant therapy in managing patients with PD.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • BDNF (Brain Derived Neurotrophic Factor)
    |
    celecoxib oral
    3ms
    Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage (clinicaltrials.gov)
    P2, N=60, Recruiting, National Taiwan University Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    celecoxib oral
    3ms
    A randomized controlled study of postoperative residual pain after vertebroplasty for osteoporotic vertebral compression fractures treated with Fu’s Subcutaneous Needling based on the theory of the tightened muscle (ChiCTR2400087270)
    P=N/A, N=60, Not yet recruiting, Suining Central Hospital; Suining central Hospital
    New trial
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    3ms
    Identification of pathogenic genes and randomized controlled drug study for primary hypertrophic osteoarthropathy (ChiCTR2400088281)
    P4, N=70, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New P4 trial
    |
    PTGR1 (Prostaglandin Reductase 1) • AKR1C1 (Aldo-Keto Reductase Family 1 Member C1) • PTGS1 (Prostaglandin-Endoperoxide Synthase 1)